Table 4.
Cox proportional models for prognostic factors
| Variables | Progression-free survival | Overall survival | ||||
|---|---|---|---|---|---|---|
| HR | 95 % CI | P value | HR | 95 % CI | P value | |
| Best objective response on target lesions | ||||||
| CR/PR | 1 | 1 | ||||
| SD | 1.67 | 0.61–4.60 | 0.23 | 4.51 | 0.95–21.4 | 0.06 |
| PD | 1.88 | 0.52–6.84 | 0.09 | 7.93 | 1.36–47.8 | 0.02 |
| NE | 3.56 | 1.00–12.9 | 0.05 | 4.88 | 1.02–23.2 | 0.04 |
| Heng risk group | ||||||
| Favorable | 1 | 1 | ||||
| Intermediate | 2.70 | 0.97–7.56 | 0.06 | 2.69 | 0.61–11.9 | 0.19 |
| Poor | 14.50 | 4.42–48.0 | 0.001 | 10.1 | 2.03–50.6 | 0.01 |
| Serum CRP level (mg/dL) | ||||||
| ≤0.3 | 1 | 1 | ||||
| 0.3< | 1.68 | 0.72–3.96 | 0.23 | 1.50 | 0.58–3.91 | 0.40 |
| Serum sodium level (mmol/L) | ||||||
| ≥135 | NA | 1 | ||||
| 135> | 1.65 | 0.63–4.30 | 0.31 | |||
| Hypertension related to sunitinib | ||||||
| Yes | 1 | NA | ||||
| No | 3.14 | 1.55–6.36 | 0.002 | |||
HR hazard ratio; CI confience interval; CR complete response; PR pertial response; SD stable disease; PD progressive disease; NE not evaluable; MSKCC Memorial Sloan Kettering Cancer Center; CRP C-reactive protein; NA not analyzed